We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
Cap. Flow
-$144M
Cap. Flow %
-5.21%
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$27.4M
2
SHPG
Shire pic
SHPG
+$25.4M
3
ILMN icon
Illumina
ILMN
+$22.1M
4
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
5
HCA icon
HCA Healthcare
HCA
+$14.3M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$72.3M
2
ALKS icon
Alkermes
ALKS
+$45.9M
3
AET
Aetna Inc
AET
+$36.3M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$23M
5
AKRX
Akorn Inc
AKRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 91.34%
2 Miscellaneous 4.98%
3 Real Estate 3.68%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
101
Novavax
NVAX
$1.54B
$3M 0.11%
+17,900
New +$2.75M
QURE icon
102
uniQure
QURE
$2.98B
$2.9M 0.11%
175,500
+72,700
+71% +$1.35M
DCOY
103
Decoy Therapeutics
DCOY
$1.88M
– –
0
– –
INSM icon
104
Insmed
INSM
$26.4B
$2.84M 0.1%
+156,600
New +$2.76M
CYNA
105
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.79M 0.1%
180,407
+131,085
+266% +$1.99M
GRFS
106
Grifois
GRFS
$5.03B
$2.69M 0.1%
166,000
– –
MDRX
107
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.67M 0.1%
173,600
-1,604,600
-90% -$23M
LXRX icon
108
Lexicon Pharmaceuticals
LXRX
$899M
$2.63M 0.1%
197,641
-156,259
-44% -$1.92M
FWP
109
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.59M 0.09%
19,507
+586
+3% +$94K
CCP
110
DELISTED
Care Capital Properties, Inc.
CCP
$2.58M 0.09%
84,316
– –
KITE
111
DELISTED
Kite Pharma, Inc.
KITE
$2.53M 0.09%
41,000
+34,700
+551% +$2.44M
DBVT
112
DBV Technologies
DBVT
$747M
$2.38M 0.09%
6,560
– –
ESPR
113
DELISTED
Esperion Therapeutics
ESPR
$2.29M 0.08%
102,800
– –
MNTA
114
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.28M 0.08%
153,700
– –
AFMD
115
DELISTED
Affimed
AFMD
$2.1M 0.08%
29,421
+6,613
+29% +$449K
GWPH
116
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.08M 0.08%
30,000
-64,000
-68% -$5.21M
TTPH
117
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.93M 0.07%
+9,616
New +$1.92M
NVRO
118
DELISTED
NEVRO CORP.
NVRO
$1.69M 0.06%
+25,000
New +$1.34M
CLDX icon
119
Celldex Therapeutics
CLDX
$3.03B
$1.66M 0.06%
7,053
-15,507
-69% -$3.38M
LKFT
120
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
$1.26M 0.05%
20,000
– –
BLCM
121
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.22M 0.04%
6,000
– –
CDTX
122
DELISTED
Cidara Therapeutics
CDTX
$901K 0.03%
2,625
+125
+5% +$37.5K
GNMK
123
DELISTED
GenMark Diagnostics, Inc
GNMK
$724K 0.03%
93,349
-121,800
-57% -$936K
CMRX
124
DELISTED
Chimerix, Inc.
CMRX
$428K 0.02%
47,800
– –
XNCR icon
125
Xencor
XNCR
$1.77B
$292K 0.01%
20,000
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management withdrew a net $144M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.

  • Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
  • Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
  • Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
  • Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
  • Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.